Related Experiment Video
Updated: Jul 26, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
THE ROLE OF BIOMARKER MACROPHAGE MIGRATION INHIBITORY FACTOR IN CARDIAC REMODELING PREDICTION IN PATIENTS WITH
Iryna R Vyshnevska1, Tatyana Storozhenko1, Mykola P Kopytsya1
1GOVERNMENT INSTITUTION "LT MALAYA THERAPY NATIONAL INSTITUTE OF THE NAMS OF UKRAINE", KHARKIV, UKRAINE.
Insights
Biomarkers macrophage migration inhibitory factor and soluble ST2 can predict adverse left ventricle remodeling after myocardial infarction. This combination offers a significant prognostic tool for post-heart attack recovery.
Area of Science:
- Cardiovascular Medicine
- Biomarker Research
- Myocardial Infarction Recovery
Background:
- Left ventricle remodeling is a key predictor of adverse outcomes after ST-segment elevation myocardial infarction (STEMI).
- Early identification of patients at risk for remodeling is crucial for timely intervention.
- Macrophage migration inhibitory factor (MIF) and soluble ST2 (sST2) are implicated in cardiac injury and remodeling processes.
Purpose of the Study:
- To evaluate the predictive value of MIF and sST2 for left ventricle remodeling six months post-STEMI.
- To develop a predictive model incorporating these biomarkers and left ventricle ejection fraction (LVEF).
Main Methods:
- A cohort of 134 STEMI patients was studied.
- No-reflow condition was defined by specific post-percutaneous coronary intervention (PCI) parameters.
- Left ventricle remodeling was assessed by changes in left ventricle volumes at 6 months.
Main Results:
- A logistic regression model was developed using MIF, sST2, and LVEF.
- The model demonstrated high predictive accuracy (AUC=0.864) for adverse left ventricle remodeling.
- The equation achieved 77% sensitivity and 85% specificity in predicting poor outcomes.
Conclusions:
- Combined MIF and sST2 levels, along with LVEF, significantly predict adverse left ventricle remodeling after STEMI.
- This biomarker panel offers a valuable tool for risk stratification in STEMI patients.
- The findings support the use of these biomarkers in clinical decision-making for post-MI care.
Objective:
The aim: To estimate the role of macrophage migration inhibitory factor and soluble ST2 in predicting the left ventricle remodeling six months after ST-segment elevation myocardial infarction.
Patients And Methods:
Materials and methods: The study involved 134 ST-segment elevation myocardial infarction patients. Occurrence of post-percutaneous coronary (PCI) intervention epicardial blood flow of TIMI <3 or myocardial blush grade 0-1 along with ST resolution <70% within 2 hours after PCI was qualified as the no-reflow condition. Left ventricle remodeling was defined after 6-months as an increase in left ventricle end-diastolic volume and/or end-systolic volume by more than 10%.
Results:
Results: A logistic regression formula was evaluated. Included biomarkers were macrophage migration inhibitory factor and sST2, left ventricle ejection fraction: Y=exp(-39.06+0.82EF+0.096ST2+0.0028MIF) / (1+exp(-39.06+0.82EF+0.096ST2+0.0028MIF)). The estimated range is from 0 to 1 point. Less than 0.5 determines an adverse outcome, and more than 0.5 is a good prognosis. This equation, with sensitivity of 77 % and specificity of 85%, could predict the development of adverse left ventricle remodeling six months after a coronary event (AUC=0.864, CI 0.673 to 0.966, p<0.05).
Conclusion:
Conclusions: A combination of biomarkers gives a significant predicting result in the formation of adverse left ventricular remodeling after ST-segment elevation myocardial infarction.
More Related Videos
08:43Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
Published on: February 14, 2017
07:25Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens
Published on: December 17, 2019
